Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
about
Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS.No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation.Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.A concentration addition model to assess activation of the pregnane X receptor (PXR) by pesticide mixtures found in the French diet.4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?A comparison of 4β-hydroxycholesterol : cholesterol and 6β-hydroxycortisol : cortisol as markers of CYP3A4 inductionEfavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.Cytochrome P450 2C9-CYP2C9.4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.Is antiarrhythmic treatment in the elderly different? a review of the specific changes.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Induction of cytochrome P450 enzymes: a view on human in vivo findings.Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.An Exposure-Response Modeling Approach to Examine the Relationship Between Potency of CYP3A Inducer and Plasma 4β-Hydroxycholesterol in Healthy Subjects.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.Evaluation of 4β-Hydroxycholesterol as a Clinical Biomarker of CYP3A4 Drug Interactions Using a Bayesian Mechanism-Based Pharmacometric Model.Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.Discovery of common urinary biomarkers for hepatotoxicity induced by carbon tetrachloride, acetaminophen and methotrexate by mass spectrometry-based metabolomics.Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin.Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine.Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic HCV Infection: A Possible Impact on the Efficacy and Safety of IFN-free Treatment.
P2860
Q34116690-A796B393-4F5B-4DE7-93A0-7846F5350899Q34299005-F970AF18-1E96-40FD-A871-B7FDC67FC88BQ34580565-3906FE91-601C-4D58-B1B1-3571F29FFCFEQ34969837-7EE1BF31-7536-49A9-9106-E18E72F60AF9Q35015993-85A5B7BC-F4F2-4B86-AF64-988F5EE9A7CDQ35174116-0B61CAC3-2AB9-4C10-BD3F-E03015F77608Q35249663-9519C131-6A98-4ED3-B391-8527B775A3ACQ35579558-3630EF2C-617A-4771-A671-E010BC77D638Q36460560-E5BF7DA3-1DE6-4F44-B7F6-A346C8D6FDD9Q36578060-D7943FF6-3B69-446F-BE98-5FD042B579BAQ36801931-DEDB4EB4-1DFB-493B-BBF6-4BF3312964BEQ36802040-7A07B4D2-37B7-45DD-8F44-6C609A8E0424Q36948140-29D6AE79-7CCC-484F-9AE3-5A071F8F99AAQ37086418-CFB9DDA4-7FD0-46D1-873D-79A6CE7DE472Q37207816-53CEF2FE-549B-48C1-9171-B949E4CE8B64Q37325725-2D52287F-B18A-46A9-857B-1D18269EB91DQ37691210-6D9146C6-BD75-41B2-815B-D11797DF3139Q37700667-3D31AC13-A36F-4A10-9B97-00857F5EDF4DQ37910895-93AC75E7-4DA0-405E-8C2D-3933783695D8Q38028549-3F6A10A0-1E04-421A-8CA7-ABE01B7E6FE8Q38057372-7D9DA897-4034-4C5E-8564-C8A7012B6239Q38813488-514F9E7F-3AD7-4C04-A018-9F217533DA9CQ39062681-CA6E7372-7662-4655-9BD1-DD0CA8B6F092Q39253133-5F1A71DB-D3E9-4C16-854A-BF1D1A8A49F4Q39800984-AA772615-E2DD-4D38-8313-3AE345D0C724Q41328717-5C6416CD-EA53-421C-9257-B8426935C14AQ41556479-2EDC8F66-5D3B-4A16-9012-E9D3390C57F6Q42653629-7D50BBA1-F8A5-45AB-B633-A34585670B8AQ42723225-F0EC1A29-C9C0-4638-85CD-679B2DCC333AQ43144692-C09BD095-4598-4B0D-9806-F6B1A477D03EQ43146767-337AAB5C-16E9-4768-9437-905BF5C3CD51Q44132038-1C04BEB4-DEBB-45B5-9543-00A0DD1625D0Q44893470-0426F729-1803-4E1D-A854-672282E02A35Q46495913-BB1DC112-6A67-4455-8E2B-FD89A3A60924Q46591319-76E64A3D-8B51-4551-BD9B-DB5C3708937FQ47400761-49FC9C47-A4DF-4447-997F-D4C2CE0E8B4FQ47702408-008D36E6-371E-4C67-868D-477F775C026AQ48156218-6A044671-E38B-4B74-95FC-51C0CA24D55EQ48283864-50CCD555-B3AE-493F-B345-553ED9A8E38CQ49567497-AE687716-5A30-4610-BFC4-2DF2E5AE1825
P2860
Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@en
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@nl
type
label
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@en
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@nl
prefLabel
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@en
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@nl
P2093
P2860
P356
P1476
Cytochrome P450 induction by r ...... rker 4beta-hydroxycholesterol.
@en
P2093
E Bredberg
K P Kanebratt
L Bertilsson
T B Andersson
T Bäckström
Y Böttiger
P2860
P304
P356
10.1038/CLPT.2008.132
P407
P577
2008-07-23T00:00:00Z